Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology. 30875124

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE We further discuss a case with a single BRAF V600E cytological mutant lacking a postoperative PTC diagnosis and discuss the limitations of BRAF V600E detection using puncture elution fluid. 31529211

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Seven of the 9 indeterminate and suspicious cases with the BRAF V600E mutation had surgical follow-up, and they were all confirmed to be PTC. 30620446

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE PTC with BRAF V600E mutation showed higher expression of ATX, LPA1, LPA2, and LPA3 than PTC without BRAF V600E mutation (p < 0.001). 31455351

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE BRAF V600E mutations occur in approximately 40% of all patients with papillary thyroid cancer (PTC) and are associated with a worse prognosis in population studies. 31085763

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE 38.2% of human PTCs displayed high expression of AXL that positively correlated with RAI-refractoriness and disease persistence or recurrence, especially when combined with v-raf murine sarcoma viral oncogene homolog B(BRAF) V600E mutation. 31181609

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Evaluation of BRAF V600E mutation status combined with cytomorphological features for diagnosis of PTC in cytologically indeterminate thyroid nodules can significantly improve diagnostic accuracy and reduce the number of diagnostic operations (calculator available at www.ptc-calc.we2host.lt). 29566402

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE The most common genetic alteration identified in papillary thyroid cancer (PTC) encodes a valine to glutamic acid change at position 600 (V600E) in the BRAF proto-oncoprotein. 30988823

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE We analyzed mutations of BRAF (V600E) and TERT promoter (C228T, C250T) in tumor DNA from 141 patients (75 with classical variant PTC, CVPTC; 66 with follicular variant PTC, FVPTC) recruited through a multi-center study. 31454788

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Detection of BRAF V600E mutation in fine-needle aspiration fluid of papillary thyroid carcinoma by droplet digital PCR. 30682328

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features. 31758408

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE TERT or NRAS mutation was likely to coexist with BRAF V600E mutation in PTC. 31300059

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE BRAF V600E mutation papillary thyroid cancer (PTC) is more aggressive with a higher risk of lymph node involvement and a poorer prognosis. 30688735

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE We conclude that coexisting BRAF V600E and TERT mutations in patients with PTC are associated with poor initial prognostic factors and clinical course and may be useful for predicting a worse response to therapy, recurrence, and poorer outcome than in patients without the above mutations. 31305897

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE BRAF V600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposure. 31135058

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE BRAF V600E and Retinoic Acid in Radioiodine-Refractory Papillary Thyroid Cancer. 30396219

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE In the Cancer Genome Atlas (TCGA) PTC cohort, higher ENS-653 expression was correlated with more frequent BRAF (V600E) mutation and poorer disease-free survival. 30940124

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE The BRAF V600E mutation was identified in 15/83 of PTCs and significantly correlated with higher age of patients and classical variant of PTC. 31085772

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE <i>BRAF</i>V600E (c.1799T>A) somatic mutation evaluation in fine needle aspiration biopsies (FNAB) is a powerful diagnostic tool in the settings of papillary thyroid cancer (PTC). 30374428

2018

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE IHC is a suitable method to screen BRAF V600E mutation in FFPE samples of CRCs and PTCs. 30009773

2018

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE The Association of BRAF V600E Mutation With Tissue Inhibitor of Metalloproteinase-3 Expression and Clinicopathological Features in Papillary Thyroid Cancer. 29868127

2018

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE The B-Raf proto-oncogene serine∕threonine kinase (BRAF) V600E (BRAF(V600E)) mutation represents a very specific marker for papillary thyroid carcinoma (PTC), including microcarcinomas (PTMCs). 30534813

2018

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE These results suggest that ZNF703 may be of potential use as a new marker for PTC prognosis and therapy that functions independent of BRAF V600E expression. 30361900

2018

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Importantly, its expression was higher in a PTC cell line that harbors BRAF V600E mutation than in a PTC cell line that harbors RET/PTC1. 29560564

2018

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE The BRAF T1799A mutation was detected in 10 PTC cases, while two different NRAS mutations in codon 61 (C181A and A182G) were found in 2 PTC cases. 30361901

2018